Idenix Pharmaceuticals Inc  

(Public, NASDAQ:IDIX)   Watch this stock  
Find more results for IDIX
24.39
+0.07 (0.27%)
Real-time:   3:11PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.32 - 24.39
52 week 2.93 - 24.39
Open 24.32
Vol / Avg. 1.49M/2.24M
Mkt cap 3.68B
P/E     -
Div/yield     -
EPS -0.92
Shares 150.86M
Beta 0.20
Inst. own 80%
Aug 4, 2014
Q2 2014 Idenix Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Jun 5, 2014
Idenix Pharmaceuticals, Inc. 2014 Annual Shareholder Meeting
May 19, 2014
Idenix Pharmaceuticals, Inc. at UBS Global Healthcare Conference
May 13, 2014
Idenix Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Idenix Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference
May 1, 2014
Q1 2014 Idenix Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -26073.99%
Operating margin - -26379.53%
EBITD margin - -25181.88%
Return on average assets -75.15% -62.41%
Return on average equity -94.24% -75.22%
Employees 84 -
CDP Score - -

Address

320 BENT STREET
CAMBRIDGE, MA 2141
United States - Map
+1-617-9959800 (Phone)
+1-617-9959801 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Officers and directors

Thomas R. Hodgson Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Ronald C. Renaud Jr. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Daniella Beckman Chief Financial Officer, Senior Vice President, Treasurer
Age: 35
Bio & Compensation  - Reuters
Jacques Dumas Ph.D. Executive Vice President, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Douglas Mayers M.D. Executive Vice President - Clinical Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Maria D. Stahl Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Paul J. Fanning Senior Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Charles A. Rowland Jr. Director
Age: 55
Bio & Compensation  - Reuters
Wayne T. Hockmeyer Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 65
Bio & Compensation  - Reuters